MCT Oil for Cognitive Function

Verdict: Weak, conflicting evidence; no reliable cognitive benefit

MCT oil reliably raises blood ketones and shows small cognitive gains in some small trials of APOE4-negative Alzheimer's/MCI patients, but the largest, most rigorous trial was fully negative, so the overall evidence is weak and conflicting with no dependable cognitive benefit, especially in healthy adults.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This claim earns a weak (Grade C) rating because the evidence is small, heterogeneous, and contradictory. Two meta-analyses found only modest signals: one (PMID 31870908, n=422) confirmed MCTs reliably raise beta-hydroxybutyrate but found just a small cognition effect (SMD -0.289) while flagging poor study design, and another (PMID 37248908) reported a general-cognition gain (SMD 0.64) concentrated almost entirely in APOE4-negative patients (SMD 1.87), with no improvement in memory, language, or attention.

Decisively, the single largest and most rigorous trial (AC-1204/NOURISH AD, PMID 32310169, n=413, 26 weeks) found no benefit even in the APOE4-negative target group (ADAS-Cog11 p=0.2458) and led to the discontinuation of the Axona drug program. The positive findings come mainly from small, short, single-center studies (e.g., PMID 31694759, n=53, 4-week crossover), and in healthy non-demented adults a systematic review (PMID 36273115) saw only weak, inconsistent working-memory effects in 4 of 6 trials.

Regulators and clinicians are correspondingly cautious. The US FDA ceased evaluating the relevant GRAS notice at the notifier's request and previously deemed the Axona MCT medical food misbranded; the UK NHS treats MCT as a clinical dietary tool and warns it can cause diarrhoea, stomach pain, or vomiting. Cleveland Clinic, Harvard Health, and the relevant specialty society are skeptical, and Mayo Clinic does not address it, so MCT oil should not be marketed or relied upon as a cognitive enhancer.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.45
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
77%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.448
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer's disease. A systematic review and meta-analysis of human studies
PMID: 31870908 2020 統合分析 n = 422
Finding: MCTs reliably elevated beta-hydroxybutyrate (MD 0.355 mmol/L, 95% CI 0.286 to 0.424). Cognition showed a small significant improvement on the combined measure (SMD -0.289, 95% CI -0.551 to -0.027) and a trend on ADAS-Cog (MD -0.539, 95% CI -1.239 to -0.161). Authors flagged heterogeneous and poor study design.
Government Effect size: BHB MD +0.355 mmol/L; cognition SMD -0.289 (small)
View on PubMed
The Effects of Medium Chain Triglyceride for Alzheimer's Disease Related Cognitive Impairment: A Systematic Review and Meta-Analysis
PMID: 37248908 2023 統合分析
Finding: MCT improved general cognition (SMD 0.64, 95% CI 0.05 to 1.24) but showed no significant gains in memory, language, or attention domains. The effect was much larger in APOE epsilon4-negative subjects (SMD 1.87, 95% CI 0.35 to 3.40) than in APOE epsilon4 carriers.
Effect size: General cognition SMD 0.64; APOE4-negative subgroup SMD 1.87
View on PubMed
A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease (NOURISH AD)
PMID: 32310169 2020 RCT (double-blind) n = 413
Finding: The largest and most rigorous trial: AC-1204 was safe and well-tolerated but produced NO cognitive benefit. ADAS-Cog11 change was 0.0 for placebo vs 0.6 for treatment (p=0.2458); all secondary outcomes also failed to detect drug effects. This negative trial led to the discontinuation of the Axona/caprylidene drug program.
🟢 High quality ⚠️ Industry-funded Effect size: ADAS-Cog11 between-group difference NS (p=0.2458)
View on PubMed
Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4-/-: A double-blind, randomized, placebo-controlled crossover trial
PMID: 31694759 2020 RCT (double-blind) n = 53
Finding: In APOE4-negative AD patients MCT reduced ADAS-Cog-C by 2.62 points vs a 2.57-point worsening on placebo (p<0.01), alongside raised beta-hydroxybutyrate and acetoacetate. Small single-center trial; short crossover phases limit durability inference.
🟠 Limited quality Effect size: ADAS-Cog-C between-group difference ~5.2 points (favoring MCT)
View on PubMed
Medium-chain triglycerides may improve memory in non-demented older adults: a systematic review of randomized controlled trials
PMID: 36273115 2022 系統性回顧
Finding: MCT supplementation was associated with improved memory indices in 4 of 6 trials, particularly working memory. Evidence is qualitative only (no meta-analysis), small trial counts, and benefit for healthy/non-demented adults is weak and inconsistent.
🟠 Limited quality Effect size: Qualitative: working-memory improvement in 4/6 RCTs; no pooled estimate
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
FDA ceased to evaluate this notice at the notifier's request source↗
L4b EU EFSA
Against
L4c UK NHS
Neutral
MCT can cause diarrhoea, stomach pain or vomiting for some people. These side effects are usually short-lived and tend to settle after a few days once the body adjusts to it. source↗
L4d TW TFDA / 衛福部
Neutral
L5a NIH Office of Dietary Supplements
Cautious
L5c Cleveland Clinic
Cautious
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Cautious
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-mct-oil-001 繁體中文版 →